Vireo Growth (VREOF) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Vireo Growth (VREOF) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.39% |
| Dec 31, 2025 | -1,323.09% |
| Sep 30, 2025 | -24.78% |
| Jun 30, 2025 | -24.45% |
| Mar 31, 2025 | 15.54% |
| Dec 31, 2024 | -4.30% |
| Sep 30, 2024 | 8.30% |
| Jun 30, 2024 | 9.72% |
| Mar 31, 2024 | 3.57% |
| Dec 31, 2023 | 162.34% |
| Sep 30, 2023 | 22.47% |
| Jun 30, 2023 | 12.75% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | 2.96% |
| Sep 30, 2022 | -56.87% |
| Jun 30, 2022 | 65.48% |
| Mar 31, 2022 | -25.50% |
| Dec 31, 2021 | -105.97% |
| Sep 30, 2021 | 2.10% |
| Jun 30, 2021 | 1.76% |